Items tagged with Scientific research
New research points out ways to improve TB vaccines (post)
A new study from the University of Pittsburgh Center for Vaccine Research published in the Journal of Experimental Medicine describes a previously unappreciated role for a class of immune cells in the early stages of tuberculosis (TB) infection.
A new dawn in the fight against TB: UNITE4TB announces start of clinical trials (post)
The UNITE4TB Consortium is proud to announce the start of its phase 2B/C clinical trial program. The announcement is a major milestone for the project and the TB community as a whole, helping to advance TB science and enhance the efficiency with which new treatments are delivered.
Longhorn Vaccines and Diagnostics presents targeted vaccine approach for Mycobacterium tuberculosis with LHNVD-301 (post)
Preclinical results indicate robust antibody activity against tuberculosis and antimicrobial resistant virus strains; Data presented at The Union World Conference on Lung Health 2023
Cancer therapy shows promise against TB (post)
A promising new cancer therapy also appears extremely potent against one of the world’s most devastating infectious diseases: tuberculosis (TB).
To build better TB vaccines, Saint Louis University researchers develop a new model by leveraging an old vaccine (post)
Each year, tuberculosis (TB) kills more people than any other infectious disease, falling out of the top spot only temporarily during the COVID-19 pandemic.
New study links blood glycerol levels to TB severity in type 2 diabetes (post)
A collaborative study between the A*STAR Infectious Diseases Labs (A*STAR ID Labs) and the University of Massachusetts (UMass) Chan Medical School has uncovered that elevated glycerol levels are responsible for increased severity of tuberculosis (TB) disease in experimental models with type 2 diabetes (T2D).
Potential therapeutic target found to combat TB, a disrupted NAD(H) homeostasis (post)
It has been uncertain how Mycobacterium tuberculosis deflects the immune response in humans, though evidence has pointed to host immunometabolism — the intrinsic link between metabolism in immune cells and their immune function. The pathogen M. tuberculosis is known to disrupt a metabolic pathway called glycolysis in infected myeloid cells, which include macrophages, through an unclear mechanism.
NIH clinical trial of TB meningitis drug regimen begins (post)
A trial of a new drug regimen to treat tuberculous meningitis (TBM) has started enrolling adults and adolescents in several countries where tuberculosis (TB) is prevalent. The Improved Management with Antimicrobial Agents Isoniazid Rifampicin Linezolid for TBM (IMAGINE-TBM) trial will compare a six-month regimen of four drugs with the nine-month, standard-of-care regimen for TBM. The study aims to generate evidence that could improve treatment for people with TBM. IMAGINE-TBM is sponsored by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, and implemented through the NIAID-funded Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections (ACTG).
Tobacco smoke exposure linked to increased risk of TB (post)
Researchers at Massachusetts General Hospital (MGH) have identified a potential mechanism by which tobacco smoking drives a type of white blood cell known as monocytes to the lung where they can increase the risk of active tuberculosis (TB).
First systematic analysis of NIH finds funding gaps for TB risk factors (post)
Tuberculosis (TB) has regained its place as the leading infectious killer worldwide. Annually, 1.6 million people die of this disease which is the equivalent to three TB deaths per minute. While the TB pandemic is driven by five key risk factors – undernutrition, HIV, alcohol use, tobacco use and diabetes – the extent of mismatch between their impact on TB and available research funding is unclear.
Page 67 of 74 · Total posts: 0
←First 66 67 68 Last→